STAT+: Pfizer says hemophilia B gene therapy significantly reduces bleeds

Pfizer said Thursday that its experimental gene therapy for hemophilia B significantly reduced the number of bleeds patients experienced over a year. 

Data from the 45-patient trial could set the stage for a second gene therapy to be approved for patients with the rare and serious bleeding disorder in as many years. In November, UniQure won approval for Hemgenix, the first hemophilia B gene therapy. 

Continue to STAT+ to read the full story…

Read Original Article: STAT+: Pfizer says hemophilia B gene therapy significantly reduces bleeds »